TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01992952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 2 x 250mg injections, received on Days 1 and 15 of cycle 1, and on day 1 of each subsequent 28 day cycle.
Study: NCT04592588

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Wait-list control
Description: Participants in the control condition will receive access to the intervention after data collection for the study has been completed.
Study: NCT01992952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: 2 x 250mg injections, received on Days 1 and 15 of cycle 1, and on day 1 of each subsequent 28 day cycle.
Study: NCT03667157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: every week IVMP therapy
Description: 12 pulses of intravenous methylprednisolone (IVMP) in every week schedule (for the first 6 weeks 0.5g IVMP per week, for the next 6 weeks 0.25g IVMP per week; cumulative dose 4.5g) according to EUGOGO recommendations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: very high doses IVMP therapy
Description: 3 pulses of intravenous methylprednisolone (IVMP) (1.0g/day for 3 consecutive days; cumulative dose 3.0g) according to EUGOGO recommendations
Study: NCT02203695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: SRT
Description: Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx
Study: NCT00314743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Study: NCT03501472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text-only PWL
Study: NCT00710021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 8% vitamin D3 powder, 84% microcrystalline cellulose, 8% fumed silica by weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 8% vitamin D3 powder, 84% microcrystalline cellulose, 8% fumed silica by weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Description: 86% microcrystalline cellulose, 14% fumed silica by weight
Study: NCT03501472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text-only PWL

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low-emot PWL

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low-emot PWL

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-emot PWL

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-emot PWL

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: immed posttest

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: immed posttest

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: immed posttest

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: delay posttest

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: delay posttest

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: delay posttest
Study: NCT00143910

Intervention type: OTHER
Intervention: observation
Study: NCT01308944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Study: NCT03858699

Intervention type: OTHER
Intervention: Recording of electroencephalographic (EEG) data
Description: Non-invasive brain activity will be measured with electroencephalography (EEG). EEG uses scalp sensors to monitor the brain's electrical activity. EEG sensors are placed on the scalp and passively record neural activity with high time resolution.

Intervention type: OTHER
Intervention: Recording of electroencephalographic (EEG) data
Description: Non-invasive brain activity will be measured with electroencephalography (EEG). EEG uses scalp sensors to monitor the brain's electrical activity. EEG sensors are placed on the scalp and passively record neural activity with high time resolution.
Study: NCT00038012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thrombopoietin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-pheresis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT02350985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol was given in a flexible dose between 40 mg to 160 mg with an escalating fashion starting at 40 mg PO AM for one week and followed by 40 mg AM and 40 mg PM for a total dose up to 160 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Venlafaxine treatment was followed as: 37.5 mg qhs for two weeks and followed 75 mg qhs with an escalating dose with 2 weeks periods up to 150 mg daily
Study: NCT01725490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
Study: NCT01011673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: ketorolac 30mg IVSS
Study: NCT04650243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid
Description: The two experimental groups will receive reduced dosage of UDCA at 250mg bid and 250mg qd respectively, while the control group will receive standard dosage of UDCA.The treatment duration will be five years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid
Description: The two experimental groups will receive reduced dosage of UDCA at 250mg bid and 250mg qd respectively, while the control group will receive standard dosage of UDCA.The treatment duration will be five years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ursodeoxycholic acid
Description: The two experimental groups will receive reduced dosage of UDCA at 250mg bid and 250mg qd respectively, while the control group will receive standard dosage of UDCA.The treatment duration will be five years.
Study: NCT00998335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long-acting bedtime insulin detemir (Levemir)
Description: This group will receive Insulin detemir. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin detemir and pre-meal insulin aspart.
Description: This group will receive Insulin detemir plus aspart. The group will start with Insulin detemir at bedtime. Then in three months they will Insulin aspart before breakfast, lunch and dinner.
Study: NCT00557947

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: intradermal and topical suturing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermabond Protape (Prineo)
Description: cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
Study: NCT04230291

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Verbal consultation
Description: Verbal consultation only without written information before receiving written action plan

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Written Action Plan
Description: Written handout of treatment plan and disease management strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Action Plan
Description: Written handout of treatment plan and disease management strategies
Study: NCT04532554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: Recombinant growth hormone will be used

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection with the same amount
Study: NCT03861208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet
Description: foods with high satiation (high protein and high fiber foods) are offered to modify children's hunger and fullness ratings postprandial

Intervention type: OTHER
Group type: OTHER
Intervention: usual diet
Description: foods representing the usually provided foods at childcare are offered
Study: NCT02286986

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabidiol
Study: NCT01825733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron
Description: Ramosetron 0.3 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: palonosetron
Description: palonosetrno 0.075 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
Study: NCT02250092

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: 10 tDCS/CIMT Sessions

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study: NCT02641496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-OSA
Description: CBT-OSA is a new cognitive behavioral therapy which focuses on changing behaviors and thoughts to help individuals adjust to using a CPAP machine.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Description: The Sleep Education treatment will include information, facts, and videos on sleep, cardiovascular disease, PTSD, and proper sleep hygiene.
Study: NCT02589561

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote fitting
Description: remote fitting of hearing aids

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote fitting
Description: remote fitting of hearing aids

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face to face fitting
Description: face to face fitting of hearing aids

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face to face fitting
Description: face to face fitting of hearing aids
Study: NCT02096315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL7080
Description: Intravenous infusion
Study: NCT01417650

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser therapy
Description: In this group, the 890 nm diode laser (Mustang 2000+, Russia) will be applied with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the joint area and painful muscles if any.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Low level laser therapy
Description: In this group, the low level laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects.
Study: NCT01911598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU will be administered as per schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as per schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered as per schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEHD7945A
Description: MEHD7945A will be administered as per schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEHD7945A
Description: MEHD7945A will be administered as per schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered as per schedule specified in the respective arm.
Study: NCT03686332

Intervention type: DRUG
Group type: OTHER
Intervention: Arm A: Atezolizumab and Radiotherapy
Description: patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion. Patients in group A will additionally receive 33 fractions of 1.5 (locoregional affected lymph nodes) and 1.8 Gy (tumor+margin) irradiation, concurrently with atezolizumab treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Arm A: Atezolizumab and Radiotherapy
Description: patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion. Patients in group A will additionally receive 33 fractions of 1.5 (locoregional affected lymph nodes) and 1.8 Gy (tumor+margin) irradiation, concurrently with atezolizumab treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Arm B: Atezolizumab
Description: patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion.

Intervention type: DRUG
Group type: OTHER
Intervention: Arm B: Atezolizumab
Description: patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion.
Study: NCT01026285

Intervention type: DRUG
Intervention: Risperidone Long-Acting injectable or oral antipsychotics
Description: According to label
Study: NCT00541398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation of guideline
Description: Outreach visits with interactive education for health staff
Study: NCT03802604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Description: Talimogene laherparepvec will be given via intra-tumoral injection at an initial dose of 10\^6 PFU/mL. On week 3 (i.e. 21 days \[± 2\] days), a second talimogene laherparepvec injection will be administered at a dose of 10\^8 PFU/mL. Third, fourth and fifth injections will be administered every 2 weeks (every 14 \[± 2\] days). The maximum volume for each injection will be 4.0 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840 mg will be administered by IV infusion on Day1 week 3, then every 2 weeks (every 14 \[± 2\] days), for a total of 4 treatment courses.
Study: NCT00701532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil and PET (brain imaging)
Description: duration 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: duration 90 days
Study: NCT03404453

Intervention type: DIAGNOSTIC_TEST
Intervention: Difficult airway incidence and prediction
Description: Paediatric patients scheduled for surgery under general anaesthesia will be examined and a set up of airway prediction tests will be performed to predict the possibility of difficult airway
Study: NCT01681888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sanger EMG Biofeedback Device
Study: NCT03166410

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cell injection
Study: NCT02167737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedside Decision Aid
Description: This group will have an initial FES and VES screening completed in the ED, the TUG test and Chair 30-Second Stand test, and the participant's risk of falling evaluated using our Bedside Decision worksheets. A study team member explains what subjects can do to decrease their risk of falling and discuss what mobility goals are the most important to them.~Participants will receive a follow-up telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm
Description: This group will also have an initial FES and VES screening completed in the ED and the same two mobility tests (TUG and Chair 30-Second Stand). Study staff will advise subjects on how to take action to prevent falls and give them a brochure, What YOU Can Do to Prevent Falls, from the CDC's STEADI Tool Kit for Health Care Providers.~Participants will receive a telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history.
Study: NCT03981562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit D
Description: Patients will take an oral vitamin D supplement once a day for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit D
Description: Patients will take an oral vitamin D supplement once a day for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Patients will take a placebo oral tablet once a day for 6 months.
Study: NCT02750280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MatriStem® [Urinary Bladder Matrix (UBM)]
Description: Porcine derived urinary bladder extracellular matrix

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex® [Silicone foam dressing]
Description: primary wound dressing
Study: NCT01182194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone/Ethinyl Estradiol (Gianvi®)
Description: 3 mg/0.02 mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YAZ®
Description: 3 mg/0.02 mg Tablets
Study: NCT00760968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-783 and methotrexate
Description: TAK-783 100 mg, tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: TAK-783 placebo-matching tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
Study: NCT04014491

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scapula control exercise
Description: To perform arm elevation in the scapular plane, subjects will be first asked to correct scapular resting posture in sitting with EMG biofeedback. Then the subjects will be instructed to do elevation in the scapular plane, side lying external rotation and dynamic hug plus with control of the scapula by EMG feedback and verbal cues

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scapular strengthening exercise
Description: The subjects in the scapular strengthening group will be asked to perform these three exercises the same as scapula control group and with the same number of trials but without any EMG biofeedback and oral cues of movement or posture correction.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03732599

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Deep Anterior Keratoplasty (S-DALK)
Description: Standard (with the use of a blade) deep anterior lamellar keratoplasty (DALK), which is a partial thickness corneal transplant, which has been shown to be a safe and effective procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IE-DALK (femtosecond)
Description: Femtosecond deep anterior lamellar keratoplasty (DALK). The femotosecond laser technology allows for the creation of precise and reproducible corneal incisions.
Study: NCT03301896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHC165
Description: LHC165 intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHC165
Description: LHC165 intratumoral injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 infusion
Study: NCT03975959

Intervention type: OTHER
Group type: OTHER
Intervention: QMRP questionnaire
Description: a single consultation for test and questionnaires for a duration of 20 minutes

Intervention type: OTHER
Group type: OTHER
Intervention: QMRP questionnaire
Description: a single consultation for test and questionnaires for a duration of 20 minutes

Intervention type: OTHER
Group type: OTHER
Intervention: QMRP questionnaire
Description: a single consultation for test and questionnaires for a duration of 20 minutes

Intervention type: OTHER
Group type: OTHER
Intervention: QMRP questionnaire
Description: a single consultation for test and questionnaires for a duration of 20 minutes
Study: NCT00287703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsating Electro-Magnetic Fields
Description: 5 days a week for 5 weeks 30 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pulsating Electro-Magnetic Fields sham
Description: sham PEMF
Study: NCT04750785

Intervention type: OTHER
Intervention: No Intervention
Description: Administered as specified in the treatment arm.
Study: NCT02938091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat diet
Description: Typical Western diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Description: Traditional Caribbean Hispanic diet
Study: NCT03306017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Three venous blood sampling before the left ventricular assist device implantation and 1 and 2 months after implantation in ambulatory patients.
Study: NCT04918446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-POSE
Description: Tablet based education and videos on opioid safety, use, and storage/disposal of the drug.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Printed instruction sheets on prescribed opioid.
Study: NCT02070224

Intervention type: OTHER
Group type: OTHER
Intervention: Serum and urine samples collections
Description: Serum and urine samples will be collected at baseline, 3 month, 6 month, 12 month to assess the predictive value of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 on OA progression (MRI, Clinical and radiological progression)

Intervention type: OTHER
Group type: OTHER
Intervention: Imaging (x-rays and MRI)
Description: MRI will be done at baseline and 12 month and x-rays will be done at baseline
Study: NCT02962167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Measles Virus
Description: Administration of MV-NIS either into the tumor bed, if surgery to remove local tumor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Measles Virus Lumbar Puncture
Description: Administration of MV-NIS into the cerebrospinal fluid via lumbar puncture
Study: NCT03661203

Intervention type: BEHAVIORAL
Intervention: Focus group
Description: Focus group for qualitative group only